Physician profile
William Bodeker
NPI 1164432068
$1,019.68
in general payments reported to CMS, 2019-2025
16 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $329 · 2023: $154 · 2024: $137 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $251.75 | 2021-2024 | Xarelto |
| Chiesi USA, INC. | $174.99 | 2021-2023 | Cleviprex, Kengreal |
| Esperion Therapeutics, INC. | $124.58 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $88.43 | 2021-2025 | Caldolor |
| Smith+Nephew, INC. | $65.98 | 2021-2024 | Collagenase Santyl |
| Amgen INC. | $46.33 | 2021-2024 | |
| Abbvie INC. | $34.38 | 2025 | |
| Pfizer INC. | $34.27 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $32.09 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $30.95 | 2025 | Xeomin, Inbrija, Ampyra |
| Sk Life Science, INC. | $27.98 | 2025 | |
| Stryker Corporation | $26.98 | 2023 | Stryker |
| Novartis Pharmaceuticals Corporation | $21.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.09 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $19.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bodeker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.